For decades, prostate cancer management has followed a single trajectory of treating earlier, treating longer, and treating more intensively. In 2026, that trajectory has split in two. The PROTEUS trial pushes intensification further into curable disease, while a parallel movement toward de-escalation is reshaping research in metastatic hormone-sensitive prostate cancer (mHSPC). Both movements rest on the same principle — matching treatment intensity to disease biology rather than applying a uniform standard across every stage.
PROTEUS: Intensification Earns its Place in Curable Disease
PROTEUS randomized 2,109 men with high-risk localized or locally advanced prostate cancer to perioperative apalutamide plus ADT versus ADT plus placebo around radical prostatectomy.[1] The results are not incremental:
- Pathological complete response or minimal residual disease rose from 1.0% with placebo to 8.9% with apalutamide — an odds ratio of 10.17.[1]
- Metastasis-free survival at 5 years improved from 73.5% to 78.2% (HR 0.80).[1]
- Event-free survival improved substantially (median 57.1 vs 38.4 months; HR 0.71).[1]
- Time to first subsequent local or systemic therapy nearly doubled (median 74.2 vs 41.5 months) — a gap approaching three years.[1]
This benefit came with a cost: grade 3–4 adverse events occurred in 39.6% of the apalutamide group versus 31.0% with placebo, driven largely by rash.[1] That trade-off matters for a curative-intent population and should temper any reflexive adoption of perioperative intensification as a blanket standard.
Notably, PROTEUS incorporated PSMA PET-CT in addition to conventional imaging into the metastasis-free survival assessment.[1] This is worth dwelling on because, as detection sensitivity increases, the definition of “metastasis-free” shifts. In an analysis using conventional imaging alone, the between-group difference in metastasis-free survival was not statistically significant. This is a reminder that imaging modality is not a neutral backdrop but an active determinant of trial endpoints and, eventually, of clinical decision-making.
mHSPC: The Same Biology Argues for De-escalation
While PROTEUS intensifies treatment upstream, mHSPC research is testing whether treatment can be safely reduced downstream. Continuous ADT — the backbone of mHSPC management for decades — carries a well-documented burden: bone loss and fracture risk, insulin resistance and weight gain, cardiovascular risk, sexual dysfunction, vasomotor symptoms, and psychological morbidity.[2][3]
The rationale for de-escalation is not ideological — it follows directly from what ADT plus an androgen receptor pathway inhibitor (ARPI) now achieves. Deep, rapid PSA responses with ADT-ARPI combinations are associated with improved overall survival, radiographic progression-free survival, and longer preservation of quality of life.[3] Studies including LIBERTAS, EORTC GUCG 2238, and A-DREAM) are evaluating whether a subgroup of patients with excellent biochemical response can transition to treatment cessation or intermittent dosing without compromising cancer control.[3]
This is not yet standard of care. A prior trial of intermittent ADT failed to demonstrate non-inferiority compared with continuous therapy, so the current generation of de-escalation studies is testing this question in the context of modern combination regimens rather than assuming the answer.[4]
One Philosophy, Two Directions
Escalation in localized disease and de-escalation in metastatic disease are not contradictory — they are sequential expressions of the same logic. Treatment intensification has historically migrated from advanced disease into earlier settings. Chemotherapy, then ARPIs, and now perioperative combinations have followed this arc, culminating in PROTEUS. Metastatic disease occupies a later point on that same curve. After years of survival gains from intensification, the question is now which patients may be able to reduce treatment intensity once disease control is secured.
The Access Question
This framework carries particular weight in settings where access to newer therapies is constrained. Perioperative ARPI intensification is now a live discussion at major meetings, while treatment options in mHSPC already include ADT-ARPI doublets with abiraterone, enzalutamide, apalutamide, or darolutamide, as well as docetaxel-based triplet regimens in selected patients.[5][4] Cost and access to therapy can influence treatment selection, adding another layer to what treatment intensity personalization means in everyday practice outside high-resource settings.
The bottom line
PROTEUS establishes that perioperative apalutamide improves pathological response and metastasis-free survival outcomes in high-risk localized or locally advanced disease, at the cost of more grade 3–4 toxicity.[1] In parallel, de-escalation trials in mHSPC are testing — but have not yet proven — that a subset of metastatic patients with deep, durable PSA responses can maintain disease control with less continuous therapy.[3] Together, these two directions define where prostate cancer management is heading: intensity calibrated to biology, response depth, and the patient’s functional priorities, not a single intensity applied uniformly across the disease spectrum.
References
1. Perioperative Apalutamide in High-Risk Localized Prostate Cancer. Taplin ME, Gleave M, Shore ND, et al. The New England Journal of Medicine. 2026;. doi:10.1056/NEJMoa2603878.
2. Prostate Cancer. Raychaudhuri R, Lin DW, Montgomery RB. JAMA. 2025;333(16):1433-1446. doi:10.1001/jama.2025.0228.
3. Advances in Androgen Deprivation Therapy-Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer. Morgans AK, Sentana-Lledo D, Wildgust M, Santos AD. Clinical Genitourinary Cancer. 2026;24(4):102536. doi:10.1016/j.clgc.2026.102536.
4. Prostate Cancer. Fonteyne V, Tree A, Castro E, Touijer K, Walz J. Lancet (London, England). 2026;407(10528):622-636. doi:10.1016/S0140-6736(25)02221-4.
5. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Shore ND, Antonarakis ES, Cookson MS, et al. The Prostate. 2020;80(6):527-544. doi:10.1002/pros.23967.